Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2191-2201

  Markakis, Konstantinos P ^a   Koropouli, Maria K ^a   Grammenou Savvoglou, Stavroula ^b   Van Winden, Ewoud C ^c   Dimitriou, Andromaxi A ^d   Demopoulos, Constantinos A ^e   Tselepis, Alexandros D ^d   Kotsifaki, Eleni E ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Regulon AE   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Heavily oxidized LDL; Lysophosphatidylcholine; Moderately oxidized LDL; Oxidized 1 palmitoyl 2 arachidonoyl phosphatidylcholine

Indexed keywords

LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1-PALMITOYL-2-(5-OXOVALEROYL)-SN-GLYCERO-3-PHOSPHORYLCHOLINE; APOLIPOPROTEIN B; ETHER PHOSPHOLIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; HYDROLYSIS; LIPID OXIDATION; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; ULTRACENTRIFUGATION; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN TRANSPORT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; APOLIPOPROTEINS B; FEMALE; HUMANS; HYDROLYSIS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; OXIDATION-REDUCTION; PHOSPHOLIPID ETHERS; PROTEIN TRANSPORT; RECEPTORS, LDL;

EID: 77956838444     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M003558     Document Type: Article

References (57)

1. th edition. W.B. Saunders Company, Philadelphia, PA.
2. Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76: 333-337.
3. nd edition. Williams & Wilkins, Baltimore, MD.
4. nd edition. International Lipid Information Bureau, New York.
5. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
6. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478.
7. Parthasarathy, S., L. G. Fong, D. Otero, and D. Steinberg. 1987. Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc. Natl. Acad. Sci. USA. 84: 537-540.
8. Steinbrecher, U. P. 1987. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262: 3603-3608.
9. Adachi, H., and M. Tsujimoto. 2006. Endothelial scavenger receptors. Prog. Lipid Res. 45: 379-404.
10. Galle, J., T. Hansen-Hagge, C. Wanner, and S. Seibold. 2006. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis. 185: 219-226.
11. Kugiyama, K., S. A. Kerns, J. D. Morrisett, R. Roberts, and P. D. Henry. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344: 160-162.
12. Morel, D. W., P. E. DiCorleto, and G. M. Chisolm. 1984. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4: 357-364.
13. Sakai, M., A. Miyazaki, H. Hakamata, T. Kodama, H. Suzuki, S. Kobori, M. Shichiri, and S. Horiuchi. 1996. The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J. Biol. Chem. 271: 27346-27352.
14. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362: 801-809.
15. Witztum, J. L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88: 1785-1792.
16. Moore, K. J., and M. W. Freeman. 2006. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26: 1702-1711.
17. Boullier, A., K. L. Gillotte, S. Horkko, S. R. Green, P. Friedman, E. A. Dennis, J. L. Witztum, D. Steinberg, and O. Quehenberger. 2000. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275: 9163-9169.
18. Terpstra, V., D. A. Bird, and D. Steinberg. 1998. Evidence that the lipid moiety of oxidized low density lipoprotein plays a role in its interaction with macrophage receptors. Proc. Natl. Acad. Sci. USA. 95: 1806-1811.
19. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
20. Bird, D. A., K. L. Gillotte, S. Horkko, P. Friedman, E. A. Dennis, J. L. Witztum, and D. Steinberg. 1999. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc. Natl. Acad. Sci. USA. 96: 6347-6352.
21. Steinbrecher, U. P., M. Lougheed, W. C. Kwan, and M. Dirks. 1989. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264: 15216-15223.
22. Tertov, V. V., V. V. Kaplun, S. N. Dvoryantsev, and A. N. Orekhov. 1995. Apolipoprotein B-bound lipids as a marker for evaluation of low density lipoprotein oxidation in vivo. Biochem. Biophys. Res. Commun. 214: 608-613.
23. Steinbrecher, U. P., and P. H. Pritchard. 1989. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 30: 305-315.
24. Stafforini, D. M., S. M. Prescott, and T. M. McIntyre. 1987. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262: 4223-4230.
25. Tselepis, A. D., and M. John Chapman. 2002. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3: 57-68.
26. Tselepis, A. D., S. A. Karabina, D. Stengel, R. Piedagnel, M. J. Chapman, and E. Ninio. 2001. N-linked glycosylation of macrophage- derived PAF-AH is a major determinant of enzyme association with plasma HDL. J. Lipid Res. 42: 1645-1654.
27. Stremler, K. E., D. M. Stafforini, S. M. Prescott, and T. M. McIntyre. 1991. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266: 11095-11103.
28. Stremler, K. E., D. M. Stafforini, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1989. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. 264: 5331-5334.
29. Fyrnys, B., C. Blencowe, and H. P. Deigner. 1995. Susceptibility of phospholipids of oxidizing LDL to enzymatic hydrolysis modulates uptake by P388D1 macrophage-like cells. FEBS Lett. 357: 7-12.
30. Liapikos, T. A., S. Antonopoulou, S. P. Karabina, D. C. Tsoukatos, C. A. Demopoulos, and A. D. Tselepis. 1994. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim. Biophys. Acta. 1212: 353-360.
31. Hakkinen, T., J. S. Luoma, M. O. Hiltunen, C. H. Macphee, K. J. Milliner, L. Patel, S. Q. Rice, D. G. Tew, K. Karkola, and S. Yla- Herttuala. 1999. Lipoprotein-associated phospholipase A(2), platelet- activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19: 2909-2917.
32. Kolodgie, F. D., A. P. Burke, K. S. Skorija, E. Ladich, R. Kutys, A. T. Makuria, and R. Virmani. 2006. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26: 2523-2529.
33. Lerman, A., and J. P. McConnell. 2008. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am. J. Cardiol. 101: 11F-22F.
34. Anderson, J. L. 2008. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am. J. Cardiol. 101: 23F-33F.
35. Daniels, L. B., G. A. Laughlin, M. J. Sarno, R. Bettencourt, R. L. Wolfert, and E. Barrett-Connor. 2008. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 51: 913-919.
36. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
37. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275.
38. Agarwal, R., and S. D. Chase. 2002. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 775: 121-126.
39. Smythe, C. D., V. O. Skinner, K. R. Bruckdorfer, D. O. Haskard, and R. C. Landis. 2003. The state of macrophage differentiation determines the TNF alpha response to nitrated lipoprotein uptake. Atherosclerosis. 170: 213-221.
40. Blank, M. L., T. Lee, V. Fitzgerald, and F. Snyder. 1981. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J. Biol. Chem. 256: 175-178.
41. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
42. Dentan, C., A. D. Tselepis, M. J. Chapman, and E. Ninio. 1996. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim. Biophys. Acta. 1299: 353-357.
43. Bartlett, G. R. 1959. Phosphorus assay in column chromatography. J. Biol. Chem. 234: 466-468.
44. Lundberg, B., K. Hong, and D. Papahadjopoulos. 1993. Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim. Biophys. Acta. 1149: 305-312.
45. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
46. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, B. Gugiu, P. L. Fox, et al. 2002. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277: 38503-38516.
47. Yang, M., E. M. Chu, M. J. Caslake, C. Edelstein, A. M. Scanu, J. S. Hill. 2010. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes. Biochim. Biophys. Acta. 1801: 176-182.
48. Turunen, P., J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyyssonen, and S. Yla-Herttuala. 2004. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. J. Lipid Res. 45: 1633-1639.
49. Parthasarathy, S., U. P. Steinbrecher, J. Barnett, J. L. Witztum, and D. Steinberg. 1985. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 82: 3000-3004.
50. Zhang, H., Y. Yang, and U. P. Steinbrecher. 1993. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J. Biol. Chem. 268: 5535-5542.
51. Horkko, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
52. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523.
53. Collot-Teixeira, S., J. Martin, C. McDermott-Roe, R. Poston, and J. L. McGregor. 2007. CD36 and macrophages in atherosclerosis. Cardiovasc. Res. 75: 468-477.
54. Kougias, P., H. Chai, P. H. Lin, A. B. Lumsden, Q. Yao, and C. Chen. 2006. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med. Sci. Monit. 12: RA5-RA16.
55. Liu-Wu, Y., E. Hurt-Camejo, and O. Wiklund. 1998. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis. 137: 351-357.
56. Sakai, M., A. Miyazaki, H. Hakamata, T. Sasaki, S. Yui, M. Yamazaki, M. Shichiri, and S. Horiuchi. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269: 31430-31435.
57. Park, C. H., M. R. Kim, J. M. Han, T. S. Jeong, and D. E. Sok. 2009. Lysophosphatidylcholine exhibits selective cytotoxicity, accompanied by ROS formation, in RAW 264.7 macrophages. Lipids. 44: 425-435.